This T32 application for a Tumor Immunology Training Program at the H. Lee Moffitt Cancer Center has the goal of training postdoctoral fellows to enter the field of translational immunology and immunotherapy of cancer. The eighteen faculty members comprise of an equal number of basic scientists and clinical investigators who have a history of working together in solving problems related to tumor immunity. Together, they form a team that addresses 3 major areas of tumor immunology 1) innate immunity, 2) adaptive immunity, and 3) immunotherapy of cancer. The approaches have been molecular, defining the signal molecules and gene regulatory components that are involved in NK cells, dendritic cells, myeloid cells, stem cells, and T cells. Antigens that can be recognized by T cells in cancer patients are also identified and means to overcome immune tolerance are sought out, based on findings in the laboratory. This environment provides an ideal setting for training of postdoctoral fellows in bench-to-bedside research as well as bedside- to-bench work. We request 2 new postdoctoral fellows, at the Ph.D. level, per year, with consecutive funding for three years, resulting in 6 total fellows by the third year. An Educational Committee, headed by Dr. Julie Djeu, with a faculty member from each of the 3 areas of research, will oversee the training. It involves a structured program with a formal research proposal from the mentor/mentee pair and regular evaluations of progress and a plan for career development. In addition to laboratory research, trainees will participate in Research-in-Progress Seminars, attend Basic and Clinical Grand Round from outside speakers, and take appropriate classes pertaining to their research. Those closer to a translational focus will have a basic as well as a clinical mentor, and will have exposure to patients in the hospital including Clinical Rounds. Experience with regulatory issues such as IRBs, INDs, and Human Safety will also be gained. State-of-the-art Core Facilities at the Cancer Center will also providing valuable training experience in numerous areas including proteomics, genomics, flow cytometry, analytical microscopy. This in-depth training will allow the postdoctoral fellow to become a successful researcher in molecular and translational immunology in academia or industry.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA115308-03
Application #
7682054
Study Section
Special Emphasis Panel (ZCA1-RTRB-A (M1))
Program Officer
Damico, Mark W
Project Start
2007-09-20
Project End
2012-08-31
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
3
Fiscal Year
2009
Total Cost
$238,219
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Santiago, Daniel N; Heidbuechel, Johannes P W; Kandell, Wendy M et al. (2017) Fighting Cancer with Mathematics and Viruses. Viruses 9:
Alexander, Lou-Ella M M; Watters, January; Reusch, Jessica A et al. (2017) Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival. Mol Immunol 91:8-16
Alexander, Lou-Ella M M; Watters, January; Reusch, Jessica A et al. (2017) Data supporting the functional role of Eleven-nineteen Lysine-rich Leukemia 3 (ELL3) in B cell lymphoma cell line cells. Data Brief 15:222-227
Basiorka, Ashley A; McGraw, Kathy L; Eksioglu, Erika A et al. (2016) The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood 128:2960-2975
Zhou, Junmin; Donatelli, Sarah S; Gilvary, Danielle L et al. (2016) Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin. Sci Rep 6:29521
Basiorka, Ashley A; McGraw, Kathy L; De Ceuninck, Leentje et al. (2016) Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41. Cancer Res 76:3531-40
Knezevic, Claire E; Wright, Gabriela; Rix, Lily L Remsing et al. (2016) Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell Chem Biol 23:1490-1503
Sahakian, Eva; Powers, John J; Chen, Jie et al. (2015) Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol Immunol 63:579-85
Zhou, Junmin; Chen, Xianghong; Gilvary, Danielle L et al. (2015) HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells. Sci Rep 5:15085
McGraw, Kathy L; Cluzeau, Thomas; Sallman, David A et al. (2015) TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget 6:34437-45

Showing the most recent 10 out of 24 publications